EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study)

Diego Ripamonti iD, Laura Comi, Andrea Francavilla, Daniela Valenti, Maria Vittoria Cossu, Davide Moschese, Giuseppe Lapadula, Luca Mezzadri, Paolo Bonfanti, Maria Mazzitelli, Annamaria Cattelan, Roberto Gulminetti und 5 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf119 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Diego Ripamonti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Piperazines, HIV Infections, Darunavir. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A dolutegravir plus darunavir/cobicistat regimen has been used as a simplified option in heavily treatment-experienced people with HIV (PWH). We report on long-term results of this regimen as assessed by treatment discontinuation (TD) for any reason.

Methods

This was a retrospective, observational, multicentre study. PWH started on dolutegravir plus darunavir/cobicistat from 1 December 2015 to 31 December 2022 were included. The primary endpoint was the rate of TD for any reason. Survival analysis with the Kaplan–Meier estimator was used to assess the probability of TD over time. Multiple Cox regression was used to estimate the probability of TD at 1 year following regimen initiation.

Results

Three hundred and twenty-seven subjects were included. At baseline, 63.6% of individuals had HIV RNA of <50 copies/mL. Primary resistance-associated mutations for NRTIs, NNRTIs, PIs and integrase inhibitors were documented in 88.0%, 70.0%, 24.5% and 6.6%, respectively. Median follow-up was 4 years (IQR 3.3–6.9). Probability of TD was 8.3%, 13.0%, 18.0%, 22.0%, 25.0%, 30.0% and 35.0% after 1, 2, 3, 4, 5, 6 and 7 years of treatment, respectively. TD occurred in 83 subjects, largely due to death (n = 20), simplification (n = 13), toxicity (n = 11), intolerance (n = 9), drug interactions (n = 10) and virological failure (n = 7). At Cox regression analysis, factors associated with a higher probability of TD over time were baseline HIV RNA of >50 copies/mL (HR = 2.14, 95% CI 1.20–3.81; P = 0.01) and the presence of PI or integrase strand transfer inhibitor resistance mutations (HR = 5.48, 95% CI 2.42–12.4; P < 0.001).

Conclusions

Dolutegravir plus darunavir/cobicistat is a durable combination in heavily treatment-experienced PWH. Those who were viraemic at the time of switch were more likely to discontinue, although most reasons for TD were other than virological failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingPiperazinesHIV InfectionsDarunavirCobicistatAnti-HIV AgentsHumansOxazinesPyridonesMaleFemaleRetrospective StudiesMiddle AgedAdultAntiretroviral Therapy, Highly ActiveDrug Resistance, ViralViral LoadDrug Therapy, CombinationTreatment OutcomeDolutegravir

Substanzen

Heterocyclic Compounds, 3-RingOxazinesPyridonesPiperazinesDarunavirCobicistatAnti-HIV AgentsDolutegravir

Autor:innen und Institutionen

  • Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • FROM-Fondazione per la Ricerca Ospedale di Bergamo-ETS, Bergamo, Italy.
  • Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy.
  • Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, Monza, Italy.
  • Infectious and Tropical Diseases Unit, Department of Molecular Medicine, Padua University Hospital, Padova, Italy.
  • Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

ORCID-Profile: Diego Ripamonti, Andrea Giacomelli

Zitieren

APA

Ripamonti, D., Comi, L., Francavilla, A., Valenti, D., Cossu, M. V., Moschese, D., Lapadula, G., Mezzadri, L., Bonfanti, P., Mazzitelli, M., Cattelan, A., Gulminetti, R., Pagnucco, L., Fabbiani, M., Bini, T., Zazzi, M., & Giacomelli, A. (2025). Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf119

Vancouver

Ripamonti D, Comi L, Francavilla A, Valenti D, Cossu MV, Moschese D, et al. Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study). Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf119

BibTeX
@article{Ripamonti2025,
  author = {Ripamonti, Diego and Comi, Laura and Francavilla, Andrea and Valenti, Daniela and Cossu, Maria Vittoria and Moschese, Davide and Lapadula, Giuseppe and Mezzadri, Luca and Bonfanti, Paolo and Mazzitelli, Maria and Cattelan, Annamaria and Gulminetti, Roberto and Pagnucco, Layla and Fabbiani, Massimiliano and Bini, Teresa and Zazzi, Maurizio and Giacomelli, Andrea},
  title = {Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf119}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche